Search research articles
Contact Us
Filters
Showing results (151-160 of 205) with videos related to
Page
of 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2019
Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
Julie E Stein, Evan J Lipson, Tricia R Cottrell, et al.
Journal of Neurosurgery. Spine
|
May 6, 2023
Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis
Emerson Lee, Xuguang Chen, Michael C LeCompte, et al.
The Oncologist
|
June 4, 2017
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
Jarushka Naidoo, Laura C Cappelli, Patrick M Forde, et al.
The American Journal of Surgical Pathology
|
August 18, 2017
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern
Genevieve J Kaunitz, Manisha Loss, Hira Rizvi, et al.
Journal for Immunotherapy of Cancer
|
June 20, 2020
Chronic immune checkpoint inhibitor pneumonitis
Jarushka Naidoo, Tricia R Cottrell, Evan J Lipson, et al.
Cell Reports
|
September 10, 2024
Aged fibroblast-derived extracellular vesicles promote angiogenesis in melanoma
Laura Hüser, Yash Chhabra, Olesia Gololobova, et al.
Cancer Immunology Research
|
August 26, 2021
Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery
Nicolas A Giraldo, Sneha Berry, Etienne Becht, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020
Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2024
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Page
of 21
Search research articles
Search
Showing results (151-160 of 205) with videos related to
Sort By:
Page
of 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2019
Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
Julie E Stein, Evan J Lipson, Tricia R Cottrell, et al.
Journal of Neurosurgery. Spine
|
May 6, 2023
Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis
Emerson Lee, Xuguang Chen, Michael C LeCompte, et al.
The Oncologist
|
June 4, 2017
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
Jarushka Naidoo, Laura C Cappelli, Patrick M Forde, et al.
The American Journal of Surgical Pathology
|
August 18, 2017
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern
Genevieve J Kaunitz, Manisha Loss, Hira Rizvi, et al.
Journal for Immunotherapy of Cancer
|
June 20, 2020
Chronic immune checkpoint inhibitor pneumonitis
Jarushka Naidoo, Tricia R Cottrell, Evan J Lipson, et al.
Cell Reports
|
September 10, 2024
Aged fibroblast-derived extracellular vesicles promote angiogenesis in melanoma
Laura Hüser, Yash Chhabra, Olesia Gololobova, et al.
Cancer Immunology Research
|
August 26, 2021
Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery
Nicolas A Giraldo, Sneha Berry, Etienne Becht, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020
Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2024
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Page
of 21